Clinical Trial

A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-23.
Trial Details
NCT Number NCT07095855
Lead Sponsor Shanghai Zhimeng Biopharma, Inc.
Conditions Chronic Hepatitis B
Enrollment 1,300 participants
Start Date 2025-08
Primary Completion 2028-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-03